| Filed On | Filing |
|---|---|
| 03 Nov 2026 | S-8 |
| 03 Nov 2026 | 10-Q |
| 03 Nov 2026 |
8-K: Results of Operations and Financial Condition
Data presented at ESMO 2026 collectively supports the potential of darovasertib to become a foundational new therapy across the treatment journey of uveal melanoma in both primary and metastatic disease, irrespective of HLA-A*02:01 allel... |
| 08 Oct 2026 |
Form 4: Hata Yujiro S, Director
Received 26,338 shares by exercise or conversion ($114K) · Sold 26,338 shares ($985K) |
| 06 Oct 2026 | 144 |
| 14 Aug 2026 | SCHEDULE 13G |
| 04 Aug 2026 | 10-Q |
| 04 Aug 2026 |
8-K: Results of Operations and Financial Condition
Registrational OptimUM-02 trial of the darovasertib combination in metastatic uveal melanoma (mUM) met its primary endpoint; new drug application (NDA) filing is underway under the real-time oncology review program (RTOR) with completion... |
| 31 Jul 2026 | SCHEDULE 13G |
| 09 Jul 2026 |
Form 4: Ruiz Briseno Andres, Chief Accounting Officer
Received 9,550 shares by exercise or conversion ($123K) · Sold 9,550 shares ($382K) |
| 07 Jul 2026 | 144 |
| 23 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders; Other Events
On June 16, 2026, IDEAYA Biosciences, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders voted on three proposals, each of which is described in mor... |
| 18 Jun 2026 |
Form 4: Yarno Wendy L, Director
Granted 20,000 Stock Option (right to buy) |
| 18 Jun 2026 |
Form 4: Stein Jeffrey, Director
Granted 20,000 Stock Option (right to buy) |
| 18 Jun 2026 |
Form 4: Rosen Terry J, Director
Granted 20,000 Stock Option (right to buy) |
| 18 Jun 2026 |
Form 4: Morrison Scott W, Director
Granted 20,000 Stock Option (right to buy) |
| 18 Jun 2026 |
Form 4: Mackey Catherine J, Director
Granted 20,000 Stock Option (right to buy) |
| 18 Jun 2026 |
Form 4: Hampton Malcolm Garret, Director
Granted 20,000 Stock Option (right to buy) |
| 10 Jun 2026 |
8-K: Other Events
Pre-Funded Warrants to Purchase 5,555,576 Shares of Common Stock |
| 09 Jun 2026 | 424B5 |
Loading...